Adrenomedullin

Overview

Adrenomedullin (AM) is a 52-amino acid peptide first isolated from human pheochromocytoma tissue in 1993 by Kitamura and colleagues. Originally discovered in the adrenal medulla, AM is now recognized as a ubiquitous peptide with potent vasodilatory, natriuretic, and cardioprotective properties. It belongs to the calcitonin gene-related peptide (CGRP) superfamily and signals through a receptor complex consisting of the calcitonin receptor-like receptor (CLR) and receptor activity-modifying protein 2 (RAMP2).

Structure and Biosynthesis

AM is derived from a 185-amino acid precursor (preproadrenomedullin) that is processed by prohormone convertases. The mature peptide contains an intramolecular disulfide bond between Cys14 and Cys19, forming a six-residue cyclic ring essential for full biological activity. The C-terminal amidation, catalyzed by peptidylglycine alpha-amidating monooxygenase (PAM), is also required for potency. AM mRNA is expressed ubiquitously, with highest levels in the adrenal medulla, heart, kidney, lung, and vascular endothelium.

Receptor and Signaling

The AM receptor complex (CLR/RAMP2) signals primarily through Gs-coupled pathways, elevating intracellular cAMP. This activates protein kinase A and downstream targets that promote smooth muscle relaxation, inhibit endothelin-1 secretion, and stimulate nitric oxide production. AM can also signal through CLR/RAMP3 (the AM2 receptor) and interacts with CGRP receptors, creating a complex signaling landscape. Intracellular AM activates MAPK/ERK pathways and promotes cell survival.

Physiological Functions

AM exerts broad cardiovascular effects including vasodilation, diuresis, natriuresis, and suppression of aldosterone secretion. It promotes renal sodium excretion independent of changes in glomerular filtration rate. AM inhibits cardiac fibroblast proliferation and reduces left ventricular remodeling. In the respiratory system, AM relaxes bronchial smooth muscle and reduces pulmonary vascular resistance. The peptide also modulates immune responses, inhibiting pro-inflammatory cytokine production.

Clinical Relevance

Circulating AM levels are elevated in hypertension, heart failure, sepsis, renal failure, and pregnancy. In heart failure, AM concentrations parallel disease severity and serve as a prognostic biomarker. Therapeutic strategies targeting AM include recombinant AM infusion for sepsis-associated hypotension and AM receptor antagonists for conditions characterized by excessive vasodilation. The CLR/RAMP2 interaction remains an attractive drug target for cardiovascular diseases.